Clinuvel Pharmaceuticals Limited (CUVL:NASDAQ) closed at $5.11 on November 12, 2026, unchanged on the day. The stock trades 42.7% below its 52-week high of $8.92 and 6.2% above its 52-week low of $4.81. Over the past year, it lost 34.9%. Clinuvel Pharmaceuticals Limited is part of the Health Care sector.
In 198 trading sessions since February 3, 2026, CUVL closed higher on 82 days (41%). Its best day was June 15, 2026 (+10.86%) and its worst was August 27, 2026 (-11.39%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 12 times.
CLINUVEL is a global biopharmaceutical company focused on developing and delivering innovative therapies for patients with genetic, metabolic, and dermatological disorders. The Company's portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. CLINUVEL is listed on the Australian Securities Exchange (ASX: CUV) with a planned listing of its American Depositary Share on the Nasdaq Stock Market (Nasdaq: CUVL). CLINUVEL's lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Canada, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP).
Find more stocks like CUVL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.